Search Results - "Laquente, B"

What treatment in 2017 for inoperable pancreatic cancers? by Taieb, J., Pointet, A.-L., Van Laethem, J.L., Laquente, B., Pernot, S., Lordick, F., Reni, M.

“…Pancreatic adenocarcinoma is a frequent and severe disease, either diagnosed as metastatic pancreatic adenocarcinoma (MPA) or as locally advanced pancreatic…”
Get full text

Biliary tract cancers: SEOM clinical guidelines by Benavides, M., Antón, A., Gallego, J., Gómez, M. A., Jiménez-Gordo, A., La Casta, A., Laquente, B., Macarulla, T., Rodríguez-Mowbray, J. R., Maurel, J.

“…Biliary tract cancer (BTC) is an uncommon and highly fatal malignancy. It is composed of three main different entities; Gall bladder carcinoma (GBC),…”
Get full text

Evolution of carbohidrated antigen 19-9 levels during neoadjuvant treatment can predict resectability and survival in borderline resectable pancreatic adenocarcinoma by Secanella, L., Busquets, J., Peláez, N., Sorribas, M., Salord, S., Laquente, B., Martínez-Carnicero, L., Leiva, D., Baena, E., Recasens, M., Peiró, I., Fabregat, J.

Get full text

Supportive care in pancreatic ductal adenocarcinoma by Laquente, B., Calsina-Berna, A., Carmona-Bayonas, A., Jiménez-Fonseca, P., Peiró, I., Carrato, A.

“…Pancreatic ductal adenocarcinoma (PDAC) is one of the cancers with poorest prognosis and represents the third leading cause of cancer-related deaths in Western…”
Get full text

Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first‐line chemotherapy in routine practice by Velasco, A. García, Macarulla, T., Sánchez, C Bugés, Martín, M., García, C., Pericay, C., Merino, S., Visa, L., Martín, T., Pedraza, M., Carnero, B., Guardeño, R., Pellín, L., Vilanova, D., Laquente, B.

Get full text

Impact of surgical margin status on long-term outcomes after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma by Pelàez, N., Secanella, L., Alberich, M., Busquets, J., Serrano, T., Laquente, B., Fabregat, J.

“…In the multivariate analysis, independent risk factors for mortality were post-pancreatectomy hemorrhage, poor differentiation and absence of adjuvant…”
Get full text

SEOM Clinical Guideline for the treatment of pancreatic cancer (2016) by Vera, R., Dotor, E., Feliu, J., González, E., Laquente, B., Macarulla, T., Martínez, E., Maurel, J., Salgado, M., Manzano, J. L.

“…Pancreatic cancer remains an aggressive disease with a 5 year survival rate of 5%. Only 15% of patients with pancreatic cancer are eligible for radical…”
Get full text

Neoadjuvant treatment in borderline resectable pancreatic adenocarcinoma by Secanella, L., Busquets, J., Peláez, N., Laquente, B., Ruiz, S., Serrano, T., Peiró, I., Berenguer, M.A., Álvarez, A., Fabregat, J.

Get full text

First-in-human dose-escalation study of VCN-01, a selective oncolytic adenovirus with hyaluronidase activity in patients with advanced or metastatic cancer by Hidalgo, M, Gil, M, Garcia-Carbonero, R, Alvarez, R, Laquente, B, Moreno, R, De Martino, A, Alemany, R, Capella, G, Blasi, E, Viaplana, I, Cascallo, M, Salazar, R

“…Background: VCN-01 is a selective oncolytic adenovirus with hyaluronid-ase activity. This study aimed to determine the safety, pharmacokinetics (PK) and…”
Get full text

Management and supportive treatment of frail patients with metastatic pancreatic cancer by Macarulla, T., Carrato, A., Díaz, R., García, A., Laquente, B., Sastre, J., Álvarez, R., Muñoz, A., Hidalgo, M.

“…Data regarding management of frail patients with pancreatic ductal adenocarcinoma practice is currently very scarce. Randomized clinical trials usually exclude…”
Get full text

Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain by Hidalgo, M., Álvarez, R., Gallego, J., Guillén-Ponce, C., Laquente, B., Macarulla, T., Muñoz, A., Salgado, M., Vera, R., Adeva, J., Alés, I., Arévalo, S., Blázquez, J., Calsina, A., Carmona, A., de Madaria, E., Díaz, R., Díez, L., Fernández, T., de Paredes, B. G., Gallardo, M. E., González, I., Hernando, O., Jiménez, P., López, A., López, C., López-Ríos, F., Martín, E., Martínez, J., Martínez, A., Montans, J., Pazo, R., Plaza, J. C., Peiró, I., Reina, J. J., Sanjuanbenito, A., Yaya, R., Carrato, Alfredo

“…The management of patients with pancreatic cancer has advanced over the last few years. We convey a multidisciplinary group of experts in an attempt to…”
Get full text

867 Metronomic Chemotherapy Following the Maximum Tolerated Dose in a Sequential Chemo-switch Schedule is an Anti-angiogenic and Effective Strategy in a Pancreas Cancer Model by Vives, M, Morell, M, Capella, G, Vinals, F, Laquente, B

Get full text

Metronomic chemotherapy: an antiangiogenic scheduling by Laquente, B, Viñals, F, Germà, J R

“…Conventional cytotoxic anticancer chemotherapeutic drugs were developed with the intent of treating cancer by direct killing or inhibition of growth of cycling…”
Get full text

Applicability and results of liver transplant combined with neoadjuvant chemo-radiotherapy in the treatment of unresectable hilar cholangiocarcinoma by Dopazo, Cristina, Lladó, L., Fondevila, C., Macarulla, T., Navalpotro, B., Ramos, E., Fabregat, J., Laquente, B., Navasa, M., Castells, L., Bilbao, I., García Valdecasas, J.C., Charco, R.

“…[Display omitted] In 2007, a multicenter protocol was developed in Catalonia, Spain, combining neoadjuvant chemoradiotherapy and liver transplantation (LT) for…”
Get full text

Clinicopathological risk factors of Stage II colon cancer: results of a prospective study by Santos, C., López-Doriga, A., Navarro, M., Mateo, J., Biondo, S., Martínez Villacampa, M., Soler, G., Sanjuan, X., Paules, M. J., Laquente, B., Guinó, E., Kreisler, E., Frago, R., Germà, J. R., Moreno, V., Salazar, R.

“…Aim  Adjuvant 5‐fluorouracil based chemotherapy has demonstrated benefit in Stage III colon cancer but still remains controversial in Stage II. The aim of this…”
Get full text

2250 Phase II trial of neoadjuvant gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy in resectable pancreatic adenocarcinoma. A GEMCAD 10–03 trial by Laquente, B, Conill, C, Fabregat, J, Cambray, M, Ayuso, J.R, Valls, C, Bombí, J.A, Serrano, T, Ferrández, A, Povés, I, Sabater, L, Montagut, C, Roselló, S, Martín-Richard, M, Díaz-Beveridge, R, Rodriguez, J, Gallego, R, García-Alb éniz, X, Fernández-Cruz, L, Maurel, J

Get full text

Neoadjuvant therapy for borderline resectable pancreatic adenocarcinoma. Preliminary results by Busquets, J, Peláez, N, Laquente, B, Verdaguer, H, Secanella, L, Rafecas, A, Torras, J, Serrano, T, Ruiz, S, Ramos, E, Fabregat, J

Get full text

TTD consensus document on the diagnosis and management of exocrine pancreatic cancer by Benavides, M., Abad, A., Ales, I., Carrato, A., Díaz Rubio, E., Gallego, J., García-Foncillas, J., Grávalos, C., Laquente, B., Pericay, C., Rivera, F., Tabernero, J., Aranda, E.

“…Exocrine pancreatic cancer (PC) is a very aggressive and heterogeneous tumor with several cellular signaling pathways implicated in its pathogenesis and…”
Get full text

SEOM Clinical Guideline for the treatment of pancreatic cancer (2016) by Vera, R., Dotor, E., Feliu, J., González, E., Laquente, B., Macarulla, T., Martínez, E., Maurel, J., Salgado, M., Manzano, J. L.

Get full text

The oncology acute toxicity unit (OATU): an outpatient facility for improving the management of chemotherapy toxicity by Majem, M, Galán, M, Pérez, F J, Muñoz, M, Chicote, S, Soler, G, Navarro, M, Martínez-Villacampa, M, García del Muro, X, Dotor, E, Laquente, B, Germà, J R

“…To provide an outpatient facility to improve the management of chemotherapy toxicity in cancer patients. We set up an oncology acute toxicity unit (OATU) to…”
Get full text